Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology Public Deposited

Downloadable Content

Download PDF
Creator
  • Chiodo, Louis A.
    • Other Affiliation: Department of Pharmacology, Texas Tech University Health Science Center, Lubbock, TX, USA
  • Mailman, Richard B.
    • Affiliation: School of Medicine, Department of Pharmacology, UNC Neuroscience Center, Neuroscience Curriculum, Neuroscience Center, Department of Psychiatry
  • Roth, Bryan
    • ORCID: https://orcid.org/0000-0002-0561-6525
    • Affiliation: School of Medicine, Department of Pharmacology, Eshelman School of Pharmacy, Division of Chemical Biology and Medicinal Chemistry, Department of Psychiatry
  • Arrington, Elaine
    • Affiliation: School of Medicine, Department of Pharmacology, UNC Neuroscience Center, Neuroscience Curriculum, Neuroscience Center, Department of Psychiatry
  • Renock, Sean
    • Other Affiliation: Department of Biochemistry, Case Western Reserve University Medical School, Cleveland, OH, USA
  • Liu, Li-Xin
    • Other Affiliation: Department of Pharmacology, Texas Tech University Health Science Center, Lubbock, TX, USA
  • Sibley, David R.
    • Other Affiliation: National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA
  • Shapiro, David A.
    • Other Affiliation: Department of Biochemistry, Case Western Reserve University Medical School, Cleveland, OH, USA
Abstract
  • Atypical antipsychotic drugs have revolutionized the treatment of schizophrenia and related disorders. The current clinically approved atypical antipsychotic drugs are characterized by having relatively low affinities for D2-dopamine receptors and relatively high affinities for 5-HT2A serotonin receptors (5-HT, 5-hydroxytryptamine (serotonin)). Aripiprazole (OPC-14597) is a novel atypical antipsychotic drug that is reported to be a high-affinity D2-dopamine receptor partial agonist. We now provide a comprehensive pharmacological profile of aripiprazole at a large number of cloned G protein-coupled receptors, transporters, and ion channels. These data reveal a number of interesting and potentially important molecular targets for which aripiprazole has affinity. Aripiprazole has highest affinity for h5-HT2B-, hD2L-, and hD3-dopamine receptors, but also has significant affinity (5–30 nM) for several other 5-HT receptors (5-HT1A, 5-HT2A, 5-HT7), as well as α1A-adrenergic and hH1-histamine receptors. Aripiprazole has less affinity (30–200 nM) for other G protein-coupled receptors, including the 5-HT1D, 5-HT2C, α1B-, α2A-, α2B-, α2C-, β1-, and β2-adrenergic, and H3-histamine receptors. Functionally, aripiprazole is an inverse agonist at 5-HT2B receptors and displays partial agonist actions at 5-HT2A, 5-HT2C, D3, and D4 receptors. Interestingly, we also discovered that the functional actions of aripiprazole at cloned human D2-dopamine receptors are cell-type selective, and that a range of actions (eg agonism, partial agonism, antagonism) at cloned D2-dopamine receptors are possible depending upon the cell type and function examined. This mixture of functional actions at D2-dopamine receptors is consistent with the hypothesis proposed by Lawler et al (1999) that aripiprazole has ‘functionally selective’ actions. Taken together, our results support the hypothesis that the unique actions of aripiprazole in humans are likely a combination of ‘functionally selective’ activation of D2 (and possibly D3)-dopamine receptors, coupled with important interactions with selected other biogenic amine receptors—particularly 5-HT receptor subtypes (5-HT1A, 5-HT2A).
Date of publication
Identifier
  • 2-s2.0-0042887023
  • doi:10.1038/sj.npp.1300203
Related resource URL
Resource type
  • Article
Rights statement
  • In Copyright
Journal title
  • Neuropsychopharmacology
Journal volume
  • 28
Journal issue
  • 8
Page start
  • 1400
Page end
  • 1411
Language
  • English
Version
  • Postprint
ISSN
  • 1740-634X
Parents:

This work has no parents.

Items